Although the estimated mean proportion of cases of tirzepatide having a lower cost of control might have been initially purported at higher targets (e.g., 52.1% at ≥20%, 75.9% at ≥25%, and 98.6% at ≥30%), this trend did not reach statistical significance due to the overlapping intervals.
← all excerpts
A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.
1
—
—